Sports drug testing using immuno-MS: Clinical study comprising administration of human chorionic gonadotropin to males

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 5, 2013, Pages 1569-1576

  Lund, Hanne ^a   Snilsberg, Ann Helene ^a   Paus, Elisabeth ^b   Halvorsen, Trine Grønhaug ^a   Hemmersbach, Peter ^a,b   Reubsaet, Léon ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clinical study; Doping analysis; Human chorionic gonadotropin; LC MS MS; Signature peptide; Tryptic digestion

Indexed keywords

DRUG PRODUCTS; MASS SPECTROMETRY; RISK ASSESSMENT; SPORTS;

CLINICAL STUDY; DOPING ANALYSIS; HUMAN CHORIONIC GONADOTROPINS; LC-MS/MS; TRYPTIC DIGESTION;

SEMICONDUCTOR DOPING;

EID: 84873714207     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6566-6     Document Type: Article

References (24)

1. Stenman U-H, Tiitinen A, Alfthan H, Valmu L (2006) The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update 12(6):769-784. doi: 10.1093/humupd/dml029
2. Handelsman DJ (2006) The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab 91(5):1646-1653. doi: 10.1210/jc.2005-2569
3. World Anti-Doping Agency (2012) The 2012 Prohibited List. Retrieved 25 Sept from http://www.wada-ama.org/Documents/World-Anti-Doping-Program/WADP- Prohibited-list/2012/WADA-Prohibited-List-2012-EN.pdf
4. Kicman AT, Brooks RV, Cowan DA (1991) Human chorionic gonadotropin and sport. Br J Sports Med 25:73-80
5. Stenman UH, Hotakainen K, Alfthan H (2008) Gonadotropins in doping: pharmacological basis and detection of illicit use. Br J Pharmacol 154(3):569-583
6. World Anti-Doping Agency (2011) Guidelines: reporting and management of human chorionic gonadotropin (hCG) findings (version 1.0 September 2011):1-8. Retrieved 25 Sept from http://www.wada-ama.org/Documents/Resources/Guidelines/ WADA-Guidelines-Reporting-Management-hCG-findings-v1.0-EN.pdf
7. Bagshawe KD (2000) Limitations of tests for human chorionic gonadotropin. Lancet 355(9205):671
8. Berger P, Sturgeon C, Bidart JM, Paus E, Gerth R, Niang M, Bristow A, Birken S, Stenman UH (2002) The ISOBM TD-7 workshop on hCG and related molecules - towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumor Biol 23(1):1-38
9. Cole LA (2009) Human chorionic gonadotropin tests. Expert Rev Mol Diagn 9(7):721-747. doi: doi:10.1586/erm.09.51
10. Cole LA, Sutton JM, Higgins TN, Cembrowski GS (2004) Between-method variation in human chorionic gonadotropin test results. Clin Chem 50(5):874-882. doi: 10.1373/clinchem.2003.026989
11. Sturgeon CM, Berger P, Bidart J-M, Birken S, Burns C, Norman RJ, Stenman U-H, on behalf of the IFCC Working Group on hCG (2009) Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem 55(8):1484-1491. doi: 10.1373/clinchem.2009.124578
12. Hemmersbach P (2008) History of mass spectrometry at the Olympic Games. J Mass Spectrom 43(7):839-853
13. Barroso O, Handelsman DJ, Strasburger C, Thevis M (2012) Analytical challenges in the detection of peptide hormones for anti-doping purposes. Bioanalysis 4(13):1577-1590. doi: 10.4155/bio.12.128
14. Thevis M, Thomas A, Schänzer W (2011) Current role of LC-MS(/MS) in doping control. Anal Bioanal Chem 401(2):405-420. doi: 10.1007/s00216-011-4859-9
15. Lund H, Løvsletten K, Paus E, Halvorsen TG, Reubsaet L (2012) Immuno MS-based targeted proteomics: highly specific, sensitive and reproducible hCG determination for clinical diagnostics and doping analysis. Anal Chem. doi: 10.1021/ac301418f
16. Lund H, Torsetnes SB, Paus E, Nustad K, Lo R, Halvorsen TG (2009) Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples. J Proteome Res 8(11):5241-5252
17. Norwegian Medicines Agency (2011) Preparatsøk. Preparatomtale. Retrieved 25 Sept from http://www.legemiddelverket.no/custom/Preparatsok/ prepSearch-80333.aspx
18. Rowland M, Tozer TN (2011) Clinical pharmacokinetics and pharmacodynamics. 4th edn. Lippincott, Williams & Wilkins, Philadelphia
19. Gam L-H, Tham S-Y, Latiff A (2003) Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis. J Chromatogr B 792(2):187-196
20. Stenman U-H, Unkila-Kallio L, Korhonen J, Alfthan H (1997) Immunoprocedures for detecting human chorionic gonadotropin: clinical aspects and doping control. Clin Chem 43(7):1293-1298
21. Handelsman DJ, Goebel C, Idan A, Jimenez M, Trout G, Kazlauskas R (2009) Effects of recombinant human LH and hCG on serum and urine LH and androgens in men. Clin Endocrin 71(3):417-428. doi: 10.1111/j.1365-2265.2008.03516.x
22. Lempiäinen A, Hotakainen K, Alfthan H, Stenman U-H (2012) Loss of human chorionic gonadotropin in urine during storage at -20 C. Clin Chim Acta 413(1-2):232-236. doi: 10.1016/j.cca.2011.09.038
23. Robinson N, Sottas P-E, Saugy M (2010) Evaluation of two immunoassays for the measurement of human chorionic gonadotropin in urine for anti-doping purposes. Clin Lab 56(5-6):197-206
24. Cole L (2009) New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrin 7(1):8